Thomas Lynch

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

Digital health technologies: opportunities & challenges in rheumatology Daniel Solomon, MD MPH & Bob Rudin, PhD Abstract The past decade in rheumatology has seen tremendous innovation in digital health technologies, including the electronic health record, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning. The increased availability of these technologies offers opportunities for improving important aspects of rheumatology, including access, outcomes, adherence and research. However, despite its growth in some areas, particularly with non-health-care consumers, digital health technology has not substantially changed the delivery of rheumatology care. This Review discusses key barriers and opportunities to improve application of digital health in rheumatology. Key topics include smart design, voice enablement and the integration of electronic patient-reported outcomes. Smart design involves active engagement with the end users of the technologies, including patients and clinicians through focus groups, user testing sessions and prototype review. Voice enablement using voice assistants could be critical for enabling patients with hand arthritis to effectively use smartphone apps and might facilitate patient engagement with many technologies. Tracking many rheumatic diseases requires frequent monitoring of #patientreportedoutcomes. Current practice only collects this information sporadically, and rarely between visits. #Digitalhealth technology could enable patient-reported outcomes to inform appropriate timing of face-to-face visits and enable improved application of treat-to-target strategies. However, best practice standards for digital health technologies do not yet exist. To achieve the potential of digital health technology in rheumatology, rheumatology professionals will need to be more engaged in the technology design process and provide leadership to effectively incorporate new tools into clinical care. Key points Digital health technology (DHT) offers enormous potential to improve rheumatology care but this potential has so far been largely unrealized. The #electronichealthrecord, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning could all have a role individually and in combination to reshape rheumatology practice. Increased use of user-centred design in the development of #digitalrheumatology tools is needed and will facilitate electronic patient-reported outcomes becoming a cornerstone of rheumatology. https://lnkd.in/eEZCSEg7

3

1 Comment

A panel of experts, led by Ryan Haumschild PharmD, MS, MBA, CPEL, discuss the impact chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have on patient quality of life and explore current treatment strategies in CLL and SLL management. Watch the series here: https://bit.ly/4aXuhr2  #CancerCare

5

Exciting developments are underway at START as we head to the #ASCO2024 Annual Meeting. We're proud to showcase the groundbreaking research led by Dr. Amita Patnaik, MD, FRCPC, Co-Director of Clinical Research at START San Antonio, through three compelling poster presentations:   1. Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors. (Co-authored by Dr. William McKean, Clinical Investigator at START Mountain Region) 2. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. 3. An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).   Join us to explore these significant advancements in cancer treatment and their implications for future research.   We encourage you to connect with our Principal Investigators at ASCO. Schedule a meeting with our team: https://lnkd.in/eicXPt2T   #OncologyResearch #ASCO2024 #ClinicalTrials

39

Dr. Harry Lander, CEO and co-founder of Canary Oncoceutics, shares his thoughts on ISMPO-CON 24 and the role of Canary Oncoceutics in shaping the future of oncology. Watch to learn how they're pushing boundaries in cancer care! #ISMPOCON24 #CanaryOncoceutics #OncologyLeadership

15

In this interview, Alex Spira, MD, PhD, FACP, FASCO, discussed post-progression results from the phase 3 MARIPOSA-2 trial, which showed that amivantamab plus chemotherapy prolonged time to treatment discontinuation and time to subsequent therapy in patients with EGFR-mutated NSCLC. "We believe this will present a new standard after disease progression on osimertinib," said Dr Spira. Check out the full video here: https://lnkd.in/ebVwQnuu #JournalOfClinicalPathways #NonSmallCellLungCancer #NSCLC #ClinicalTrial 

2

Join Taylor Lipsich from PatientWing as she explores 'How Building Trust with Rare Disease Patients Accelerates Trial Enrollment' at the 20th Biopharma Clinical Trials Nexus in San Diego. Don't miss this insightful discussion! #NEXUSconference #Patientwing #BioPharmaNexus #raredisease

40

4 Comments

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP https://lnkd.in/epsHT5q9

8

What are the costs of #medications for #patients with #erectiledysfunction who are treated with PDE-5 inhibitors? Our resident, Ellen Cahill, MD, sits down with Urology Times to discuss the background and notable findings from the study "Trends in Phosphodiesterase Type 5 Inhibitor #Prescriptions and Cost: #Medicare Analysis 2017-2021." Read or watch the interview to learn more ⬇ Yale School of Medicine | MJH Life Sciences® | Piruz Motamedinia, MD | Michelle Ross

8

The Prelude team was in San Diego this week for the American Society of Hematology (ASH) Annual Meeting, where we shared the first interim clinical data from our ongoing open-label, dose-escalation trial of PRT2527, our potent and highly selective CDK9 inhibitor. “CDK9 has long been considered a potential therapeutic approach for treating hematologic malignancies and a highly selective CDK9 inhibitor was sought to minimize off target toxicity,” says Jane Huang, M.D., Prelude's President and Chief Medical Officer. “We are encouraged by the results demonstrated to date by PRT2527 both as a monotherapy and particularly in combination with zanubrutinib resulting in an overall response rate of 38.5% including two patients with aggressive lymphomas who had received prior CAR-T therapy. These results represent a positive step for CDK9 inhibition as a possible future therapeutic approach for patients with aggressive hematologic cancers with limited treatment options.” For details, see our press release below or visit our website at preludetx.com. #ASH24 #precisiononcology #Cancerresearch

49

1 Comment

Offering in-office biologic therapies 🧪 to ankylosing spondylitis patients is an innovative approach that can significantly ✅ enhance patient care.

1

FDA adverse event study shows JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://buff.ly/3xS9dV9

1

Bispecific antibody therapy is emerging as a promising option for patients with advanced cancer. Lee Pendleton, PharmD, from Arizona Oncology in Prescott, helps patients and their families better understand how this innovative therapy works, its potential benefits, and what to expect. 📖arizonaoncology.com/blog #BispecificAntibodies #CancerTherapy #Oncology #AdvancedCancer #Pharmacology #PatientCare #Prescott #Arizona

5

In our latest Oncology Overdrive episode, host Shikha Jain, MD, speaks with Shyam Natarajan, PhD, about machine learning in cancer research and testing, using technological innovation to address disparities in health care trials and more. 🎧 Listen here 🎧 https://lnkd.in/e7Bdtrn2

1

🌟 EXPERT INSIGHTS: Christopher Bunick, MD, PhD, discusses what he calls a “next-generation TYK2 inhibitor,” #zasocitinib, highlighting its high selectivity and potency and spotlighting data from clinical trials shared at the European Society for Dermatological Research meeting. "I think that the goal of this poster and this presentation at ESDR was to really show the dermatology community that there is so much more that can be done to inhibit the TYK2 pathway," Bunick said. 🎥 View the full interview now: https://lnkd.in/gaRpukWc

55